Current and historical daily PE Ratio for HAEMATO AG (
) from 2018 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. HAEMATO AG stock (LTS:0VZ7) PE ratio as of Jun 21 2024 is 8.17.
More Details
HAEMATO AG (LTS:0VZ7) PE Ratio (TTM) Chart
HAEMATO AG (LTS:0VZ7) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 790
- 1
- 2
- 3
- 4
- 5
- 6
- 9
HAEMATO AG PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-21 | 15.2 | 2024-04-18 | 15.2 |
2024-06-19 | 15.2 | 2024-04-17 | 15.2 |
2024-06-18 | 15.2 | 2024-04-16 | 15.2 |
2024-06-17 | 15.2 | 2024-04-15 | 15.2 |
2024-06-14 | 15.2 | 2024-04-12 | 15.2 |
2024-06-13 | 15.2 | 2024-04-11 | 15.2 |
2024-06-12 | 15.2 | 2024-04-10 | 15.2 |
2024-06-11 | 15.2 | 2024-04-09 | 15.2 |
2024-06-10 | 15.2 | 2024-04-08 | 15.2 |
2024-06-07 | 15.2 | 2024-04-05 | 15.2 |
2024-06-06 | 15.2 | 2024-04-04 | 15.2 |
2024-06-05 | 15.2 | 2024-04-03 | 15.2 |
2024-06-04 | 15.2 | 2024-04-02 | 15.2 |
2024-06-03 | 15.2 | 2024-04-01 | 15.2 |
2024-05-31 | 15.2 | 2024-03-29 | 15.2 |
2024-05-30 | 15.2 | 2024-03-28 | 15.2 |
2024-05-29 | 15.2 | 2024-03-27 | 15.2 |
2024-05-28 | 15.2 | 2024-03-26 | 15.2 |
2024-05-27 | 15.2 | 2024-03-25 | 15.2 |
2024-05-24 | 15.2 | 2024-03-22 | 15.2 |
2024-05-23 | 15.2 | 2024-03-21 | 15.2 |
2024-05-22 | 15.2 | 2024-03-20 | 15.2 |
2024-05-21 | 15.2 | 2024-03-19 | 15.2 |
2024-05-20 | 15.2 | 2024-03-18 | 15.2 |
2024-05-17 | 15.2 | 2024-03-15 | 15.2 |
2024-05-16 | 15.2 | 2024-03-14 | 15.2 |
2024-05-15 | 15.2 | 2024-03-13 | 15.2 |
2024-05-14 | 15.2 | 2024-03-12 | 15.2 |
2024-05-13 | 15.2 | 2024-03-11 | 15.2 |
2024-05-10 | 15.2 | 2024-03-08 | 15.2 |
2024-05-09 | 15.2 | 2024-03-07 | 15.2 |
2024-05-08 | 15.2 | 2024-03-06 | 15.2 |
2024-05-07 | 15.2 | 2024-03-05 | 15.2 |
2024-05-06 | 15.2 | 2024-03-04 | 15.2 |
2024-05-03 | 15.2 | 2024-03-01 | 15.2 |
2024-05-02 | 15.2 | 2024-02-29 | 15.2 |
2024-05-01 | 15.2 | 2024-02-28 | 15.2 |
2024-04-30 | 15.2 | 2024-02-27 | 15.2 |
2024-04-29 | 15.2 | 2024-02-26 | 15.2 |
2024-04-26 | 15.2 | 2024-02-23 | 15.2 |
2024-04-25 | 15.2 | 2024-02-22 | 15.2 |
2024-04-24 | 15.2 | 2024-02-21 | 15.2 |
2024-04-23 | 15.2 | 2024-02-20 | 15.2 |
2024-04-22 | 15.2 | 2024-02-19 | 15.2 |
2024-04-19 | 15.2 | 2024-02-16 | 15.2 |
HAEMATO AG (LTS:0VZ7) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
HAEMATO AG
ISIN : DE000A289VV1
Compare
Compare
Traded in other countries / regions
HAEK.Germany0VZ7.UK IPO Date
2018-01-25Description
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.